Effectiveness of Messenger RNA Coronavirus Disease 2019 Vaccines Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infections During the Delta Variant Epidemic in Japan: Vaccine Effectiveness Real-time Surveillance for SARS-CoV-2 (VERSUS)

被引：16

作者：

Maeda, Haruka ^{[1
,2
]}

Saito, Nobuo ^{[3
]}

Igarashi, Ataru ^{[4
,5
]}

Ishida, Masayuki ^{[6
]}

Suami, Kazuya ^{[7
]}

Yagiuchi, Ai ^{[7
]}

Kimura, Yuya ^{[8
]}

Komino, Masaru ^{[8
]}

Arai, Hiromi ^{[8
]}

Morikawa, Toru ^{[9
]}

Motohashi, Iori ^{[10
]}

Miyazawa, Rei ^{[10
]}

Moriyama, Tetsu ^{[11
]}

Kamura, Hiroshi ^{[12
]}

Terada, Mayumi ^{[13
]}

Kuwamitsu, Osamu ^{[14
]}

Hayakawa, Tomoichiro ^{[15
]}

Sando, Eiichiro ^{[16
,17
]}

Ohara, Yasuji ^{[18
]}

Teshigahara, Osamu ^{[19
]}

Suzuki, Motoi ^{[20
]}

Morimoto, Konosuke ^{[1
]}

机构：

[1] Nagasaki Univ, Inst Trop Med, Dept Resp Infect, 1-12-4 Sakamoto, Nagasaki 8528523, Japan

[2] Nagasaki Univ, Dept Clin Trop Med, Grad Sch Biomed Sci, Nagasaki, Japan

[3] Oita Univ, Fac Med, Dept Microbiol, Oita, Japan

[4] Yokohama City Univ, Unit Publ Hlth & Prevent Med, Sch Med, Yokohama, Kanagawa, Japan

[5] Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Hlth Econ & Outcomes Res, Tokyo, Japan

[6] Chikamori Hosp, Kochi, Japan

[7] Nagoya Ekisaikai Hosp, Nagoya, Aichi, Japan

[8] Saiseikai Kurihashi Hosp, Saitama, Japan

[9] Nara City Hosp, Nara, Japan

[10] Kawasaki Municipal Tama Hosp, Kawasaki, Kanagawa, Japan

[11] Moriyama Mem Hosp, Tokyo, Japan

[12] Loco Clin Nakameguro, Tokyo, Japan

[13] Nijigaoka Hosp, Nagasaki, Japan

[14] Gohongi Clin, Tokyo, Japan

[15] Hayakawa Internal Med Clin, Fukuoka, Japan

[16] Kita Fukushima Med Ctr, Fukushima, Japan

[17] Fukushima Med Univ, Fukushima, Japan

[18] Takagi Hosp, Nagoya, Aichi, Japan

[19] Mizuho St Clin, Nagoya, Aichi, Japan

[20] Natl Inst Infect Dis, Infect Dis Surveillance Ctr, Tokyo, Japan

来源：

CLINICAL INFECTIOUS DISEASES | 2022年 / 75卷 / 11期

关键词：

SARS-CoV-2; COVID-19; vaccine effectiveness; Delta; Japan;

D O I：

10.1093/cid/ciac292

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

This multicenter test-negative case-control study showed messenger RNA COVID-19 vaccine effectiveness against symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections in Japan during July-September 2021: 88.7% among people aged 16-64 years and 90.3% among those aged >= 65 years. Background Although high vaccine effectiveness of messenger RNA (mRNA) coronavirus disease 2019 (COVID-19) vaccines has been reported in studies in several countries, data are limited from Asian countries, especially against the Delta (B.1.617.2) variant. Methods We conducted a multicenter test-negative case-control study in patients aged >= 16 years visiting hospitals or clinics with signs or symptoms consistent with COVID-19 from 1 July to 30 September 2021, when the Delta variant was dominant (>= 90% of SARS-CoV-2 infections) nationwide in Japan. Vaccine effectiveness of BNT162b2 or mRNA-1273 against symptomatic SARS-CoV-2 infections was evaluated. Waning immunity among patients aged 16-64 years was also assessed. Results We enrolled 1936 patients, including 396 test-positive cases and 1540 test-negative controls for SARS-CoV-2. The median age was 49 years, 53.4% were male, and 34.0% had underlying medical conditions. Full vaccination (receiving 2 doses >= 14 days before symptom onset) was received by 6.6% of cases and 38.8% of controls. Vaccine effectiveness of full vaccination against symptomatic SARS-CoV-2 infections was 88.7% (95% confidence interval [CI], 78.8%-93.9%) among patients aged 16-64 years and 90.3% (95% CI, 73.6%-96.4%) among patients aged >= 65 years. Among patients aged 16-64 years, vaccine effectiveness was 91.8% (95% CI, 80.3%-96.6%) within 1-3 months after full vaccination, and 86.4% (95% CI, 56.9%-95.7%) within 4-6 months. Conclusions mRNA COVID-19 vaccines had high effectiveness against symptomatic SARS-CoV-2 infections in Japan during July-September 2021, when the Delta variant was dominant nationwide.

引用

页码：1971 / 1979

页数：9

共 50 条

[21] A review of metallic nanostructures against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Istuti Saraswat
Sarmistha Saha
Anuja Mishra
Toxicology and Environmental Health Sciences, 2023, 15 : 315 - 324
[22] A review of metallic nanostructures against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Saraswat, Istuti
Saha, Sarmistha
Mishra, Anuja
TOXICOLOGY AND ENVIRONMENTAL HEALTH SCIENCES, 2023, 15 (04) : 315 - 324
[23] Inhibitors of Protein Glycosylation Are Active against the Coronavirus Severe Acute Respiratory Syndrome Coronavirus SARS-CoV-2
Rajasekharan, Sreejith
Milan Bonotto, Rafaela
Nascimento Alves, Lais
Kazungu, Yvette
Poggianella, Monica
Martinez-Orellana, Pamela
Skoko, Natasa
Polez, Sulena
Marcello, Alessandro
VIRUSES-BASEL, 2021, 13 (05):
[24] Comormaities and Symptomatology of SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2)-Related Myocarditis and SARS-CoV-2 Vaccine-Related Myocarditis: A Review
Cushion, Sarah
Arboleda, Vania
Hasanain, Yousef
Beckler, Michelle Demory
Hardigan, Patrick
Kesselman, Marc M.
CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (04)
[25] Detection of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) by Mass Spectrometry
Wandernoth, Petra
Kriegsmann, Katharina
Groh-Mohanu, Cristina
Daeumer, Martin
Gohl, Peter
Harzer, Oliver
Kriegsmann, Mark
Kriegsmann, Joerg
VIRUSES-BASEL, 2020, 12 (08):
[26] The landscape of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) genomic mutations
Lippi, Giuseppe
Henry, Brandon M.
JOURNAL OF LABORATORY AND PRECISION MEDICINE, 2022, 7
[27] The landscape of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) genomic mutations
Lippi, Giuseppe
Henry, Brandon M.
JOURNAL OF LABORATORY AND PRECISION MEDICINE, 2022, 7
[28] Smoking and the Risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection
Lee, Sang Chul
Son, Kang Ju
Kim, Dong Wook
Han, Chang Hoon
Choi, Yoon Jung
Kim, Seong Woo
Park, Seon Cheol
NICOTINE & TOBACCO RESEARCH, 2021, 23 (10) : 1787 - 1792
[29] The Impact of Cocirculating Pathogens on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)/Coronavirus Disease 2019 Surveillance: How Concurrent Epidemics May Introduce Bias and Decrease the Observed SARS-CoV-2 Percentage Positivity
Kovacevic, Aleksandra
Eggo, Rosalind M.
Baguelin, Marc
de Celles, Matthieu Domenech
Opatowski, Lulla
JOURNAL OF INFECTIOUS DISEASES, 2022, 225 (02) : 199 - 207
[30] Comparative effectiveness of the sars-CoV-2 vaccines during delta dominance
Islam, Nazmul
Griffin, Daniel O.
Jarvis, Megan S.
Cohen, Kenneth
HELIYON, 2023, 9 (05)

← 1 2 3 4 5 →